309 related articles for article (PubMed ID: 2881923)
1. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
Faraone SV; Brown WA; Laughren TP
J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
[TBL] [Abstract][Full Text] [Related]
2. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
3. Reducing the dose of depot neuroleptics in stable schizophrenia.
Dale R; Longdon M; Seeman MV
J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
[TBL] [Abstract][Full Text] [Related]
4. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
Csernansky JG; Kaplan J; Holman CA; Hollister LE
Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
[TBL] [Abstract][Full Text] [Related]
5. Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome.
Heresco-Levy U; Greenberg D; Lerer B; Dasberg H; Brown WA
J Clin Psychiatry; 1993 Feb; 54(2):59-62. PubMed ID: 8095259
[TBL] [Abstract][Full Text] [Related]
6. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
Young AS; Faraone SV; Brown WA
J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
[TBL] [Abstract][Full Text] [Related]
7. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
[TBL] [Abstract][Full Text] [Related]
8. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
Woggon B; Bickel P; Schnyder B
Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
[TBL] [Abstract][Full Text] [Related]
9. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
[TBL] [Abstract][Full Text] [Related]
10. Relations between psychotic symptoms and serum prolactin levels.
Roncoroni D
Pharmacopsychiatry; 1989 Mar; 22(2):71-5. PubMed ID: 2566181
[TBL] [Abstract][Full Text] [Related]
11. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.
Suzuki K; Awata S; Takano T; Ebina Y; Iwasaki H; Matsuoka H
Psychiatry Clin Neurosci; 2005 Aug; 59(4):481-9. PubMed ID: 16048455
[TBL] [Abstract][Full Text] [Related]
12. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
Nakajima M; Terao T; Iwata N; Nakamura J
Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
[TBL] [Abstract][Full Text] [Related]
13. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
14. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
Steingard S; Allen M; Schooler NR
J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic medication: clinical guidelines for maintenance therapy.
Johnson DA
J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
[TBL] [Abstract][Full Text] [Related]
16. Basal and stimulated levels of prolactin, TSH and LH in serum of chronic schizophrenic patients, long-term treated with neuroleptics.
Naber D; Ackenheil M; Laakman G; Fischer H; von Werder K
Pharmakopsychiatr Neuropsychopharmakol; 1980 Nov; 13(6):325-30. PubMed ID: 6111094
[TBL] [Abstract][Full Text] [Related]
17. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
[TBL] [Abstract][Full Text] [Related]
18. Inpatient violence and the schizophrenic patient: an inverse correlation between danger-related events and neuroleptic levels.
Yesavage JA
Biol Psychiatry; 1982 Nov; 17(11):1331-7. PubMed ID: 7150681
[TBL] [Abstract][Full Text] [Related]
19. Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients.
Lindenmayer JP; Smith D; Katz I
J Clin Psychiatry; 1984 Mar; 45(3):117-9. PubMed ID: 6142035
[TBL] [Abstract][Full Text] [Related]
20. Basal and stimulated levels of prolactin, TSH, and LH in serum of chronic schizophrenic patients long-term treated with neuroleptics: relations to psychopathology.
Naber D; Ackenheil M; Laakmann G
Adv Biochem Psychopharmacol; 1980; 24():419-23. PubMed ID: 6105792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]